Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies.

Jenkins, Alicia J; Grant, Maria B; Busik, Julia V

Jenkins, Alicia J; Grant, Maria B; Busik, Julia V.

Affiliation

Jenkins AJ; NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia.
Grant MB; Department of Ophthalmology and Vision Science, University of Alabama at Birmingham, Birmingham, AL, USA.
Busik JV; Department of Physiology, Michigan State University, East Lansing, MI, USA. busik@msu.edu.

Diabetologia ; 65(4): 587-603, 2022 04.

Article in En | MEDLINE | ID: mdl-35149880

Subject(s)

Diabetes Mellitus; Diabetic Retinopathy; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Cholesterol; Diabetes Mellitus/drug therapy; Diabetic Retinopathy/drug therapy; Fibric Acids/therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use; Lipids/chemistry; Retina/physiopathology

Key words

Cholesterol; Cholesterol crystals; Diabetic retinopathy; Dyslipidaemia; Fibrate; Hyperreflective crystalline deposits; Lipids; Review; Statin

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / Diabetes Mellitus / Diabetic Retinopathy Limits: Humans Language: En Journal: Diabetologia Year: 2022 Type: Article Affiliation country: Australia

Fulltext

XML

PubMed Links

Search on Google